FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2793340325> ?p ?o ?g. }

• W2793340325 endingPage "214" @default.
• W2793340325 startingPage "203" @default.
• W2793340325 abstract "Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We evaluated the effect of concomitant methotrexate (MTX) or glucocorticoid (GC) use on tofacitinib clinical efficacy. Data were pooled from two open-label, long-term extension studies of tofacitinib 5 or 10 mg twice daily in patients with RA. Response according to Clinical Disease Activity Index (CDAI) was assessed separately in patients who discontinued (no MTX/GC use within 30 days prior to year-3 visit; assessment at month 3/year 3) or initiated (on/before year 3; assessment at initiation and year 3) MTX/GC. By year 3, among patients receiving background MTX at baseline, 186/1608 (11.6%) discontinued MTX, and 319/1434 (22.2%) patients receiving GC at baseline discontinued GC. Overall, 70.4/69.1% of patients who discontinued/continued MTX and 72.7/65.9% who discontinued/continued GC achieved CDAI remission or low disease activity (LDA) at year 3. Month 3 remission/LDA rates were maintained at year 3 in the majority of patients, irrespective of MTX/GC discontinuation/continuation. By year 3, 6.2% of patients receiving tofacitinib without MTX at baseline had initiated concomitant MTX, and 25.1% receiving tofacitinib without GC initiated GC; 69.0% and 45.4% initiating MTX or GC, respectively, had a CDAI-defined incomplete response prior to initiation. RA signs/symptoms improved following MTX initiation; only modest improvement was observed with GC initiation. Patients achieving remission/LDA with tofacitinib may discontinue MTX or GC and maintain treatment response. Patients with an incomplete response may benefit from adding concomitant MTX. Pfizer Inc. Study A3921024 [NCT00413699] and Study A3921041 [NCT00661661]." @default.
• W2793340325 created "2018-03-29" @default.
• W2793340325 creator A5013299756 @default.
• W2793340325 creator A5025867925 @default.
• W2793340325 creator A5035639364 @default.
• W2793340325 creator A5046261111 @default.
• W2793340325 creator A5047117557 @default.
• W2793340325 creator A5053677467 @default.
• W2793340325 creator A5057538503 @default.
• W2793340325 creator A5084803961 @default.
• W2793340325 creator A5086564157 @default.
• W2793340325 creator A5090337589 @default.
• W2793340325 date "2018-02-07" @default.
• W2793340325 modified "2023-10-17" @default.
• W2793340325 title "Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis" @default.
• W2793340325 cites W1974321634 @default.
• W2793340325 cites W1990105300 @default.
• W2793340325 cites W2000972571 @default.
• W2793340325 cites W2014330392 @default.
• W2793340325 cites W2035320881 @default.
• W2793340325 cites W2038992287 @default.
• W2793340325 cites W2046744512 @default.
• W2793340325 cites W2069302785 @default.
• W2793340325 cites W2069871920 @default.
• W2793340325 cites W2097302763 @default.
• W2793340325 cites W2101217991 @default.
• W2793340325 cites W2120393706 @default.
• W2793340325 cites W2121133349 @default.
• W2793340325 cites W2129603347 @default.
• W2793340325 cites W2129948300 @default.
• W2793340325 cites W2133103918 @default.
• W2793340325 cites W2138609584 @default.
• W2793340325 cites W2142004396 @default.
• W2793340325 cites W2149447280 @default.
• W2793340325 cites W2152348310 @default.
• W2793340325 cites W2153414586 @default.
• W2793340325 cites W2164858045 @default.
• W2793340325 cites W2254470680 @default.
• W2793340325 cites W2265836205 @default.
• W2793340325 cites W2626892937 @default.
• W2793340325 doi "https://doi.org/10.1007/s40744-018-0093-7" @default.
• W2793340325 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5935624" @default.
• W2793340325 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29417430" @default.
• W2793340325 hasPublicationYear "2018" @default.
• W2793340325 type Work @default.
• W2793340325 sameAs 2793340325 @default.
• W2793340325 citedByCount "10" @default.
• W2793340325 countsByYear W27933403252018 @default.
• W2793340325 countsByYear W27933403252019 @default.
• W2793340325 countsByYear W27933403252020 @default.
• W2793340325 countsByYear W27933403252021 @default.
• W2793340325 countsByYear W27933403252022 @default.
• W2793340325 countsByYear W27933403252023 @default.
• W2793340325 crossrefType "journal-article" @default.
• W2793340325 hasAuthorship W2793340325A5013299756 @default.
• W2793340325 hasAuthorship W2793340325A5025867925 @default.
• W2793340325 hasAuthorship W2793340325A5035639364 @default.
• W2793340325 hasAuthorship W2793340325A5046261111 @default.
• W2793340325 hasAuthorship W2793340325A5047117557 @default.
• W2793340325 hasAuthorship W2793340325A5053677467 @default.
• W2793340325 hasAuthorship W2793340325A5057538503 @default.
• W2793340325 hasAuthorship W2793340325A5084803961 @default.
• W2793340325 hasAuthorship W2793340325A5086564157 @default.
• W2793340325 hasAuthorship W2793340325A5090337589 @default.
• W2793340325 hasBestOaLocation W27933403251 @default.
• W2793340325 hasConcept C126322002 @default.
• W2793340325 hasConcept C141071460 @default.
• W2793340325 hasConcept C2776233030 @default.
• W2793340325 hasConcept C2777575956 @default.
• W2793340325 hasConcept C2778715236 @default.
• W2793340325 hasConcept C2778886723 @default.
• W2793340325 hasConcept C2779384505 @default.
• W2793340325 hasConcept C2781059491 @default.
• W2793340325 hasConcept C71924100 @default.
• W2793340325 hasConcept C90924648 @default.
• W2793340325 hasConceptScore W2793340325C126322002 @default.
• W2793340325 hasConceptScore W2793340325C141071460 @default.
• W2793340325 hasConceptScore W2793340325C2776233030 @default.
• W2793340325 hasConceptScore W2793340325C2777575956 @default.
• W2793340325 hasConceptScore W2793340325C2778715236 @default.
• W2793340325 hasConceptScore W2793340325C2778886723 @default.
• W2793340325 hasConceptScore W2793340325C2779384505 @default.
• W2793340325 hasConceptScore W2793340325C2781059491 @default.
• W2793340325 hasConceptScore W2793340325C71924100 @default.
• W2793340325 hasConceptScore W2793340325C90924648 @default.
• W2793340325 hasIssue "1" @default.
• W2793340325 hasLocation W27933403251 @default.
• W2793340325 hasLocation W27933403252 @default.
• W2793340325 hasLocation W27933403253 @default.
• W2793340325 hasLocation W27933403254 @default.
• W2793340325 hasOpenAccess W2793340325 @default.
• W2793340325 hasPrimaryLocation W27933403251 @default.
• W2793340325 hasRelatedWork W1984540686 @default.
• W2793340325 hasRelatedWork W1998887580 @default.
• W2793340325 hasRelatedWork W2014330392 @default.
• W2793340325 hasRelatedWork W2054078006 @default.
• W2793340325 hasRelatedWork W2755978387 @default.
• W2793340325 hasRelatedWork W2793340325 @default.

• next